XML 21 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)
 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2008
Glaxo, Smith, Kline
Project
Jun. 30, 2012
Glaxo, Smith, Kline
Jun. 30, 2011
Glaxo, Smith, Kline
Jun. 30, 2012
Glaxo, Smith, Kline
Jun. 30, 2011
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Sep. 30, 2006
Astra Zeneca
Jun. 30, 2012
Astra Zeneca
Jun. 30, 2012
Astra Zeneca
Dec. 31, 2008
Astra Zeneca
Dec. 31, 2011
Astra Zeneca
Oct. 31, 2011
Astra Zeneca
Amendment
Dec. 31, 2011
Astra Zeneca
Amendment
Advance the program following completion of Phase 2a
May 31, 2012
National Institutes of Health
Fund Research
May 31, 2012
National Institutes of Health
Business Development
Jul. 31, 2011
National Institutes of Health
HPV
Sep. 30, 2008
National Institutes of Health
ISS Technology
Product Information [Line Items]                                          
Number of programs for research and early clinical development         4                                
Collaboration revenue $ 1,623,000 $ 6,363,000 $ 2,552,000 $ 6,729,000 $ 10,000,000               $ 10,000,000     $ 3,000,000 $ 2,600,000        
Revenue from milestone payment                 6,000,000 15,000,000   200,000 400,000 4,500,000     20,000,000        
Deferred revenue recognition period         7 years             5 years 5 years   5 years            
Revenue of deferred revenue           400,000 400,000 700,000 700,000                        
Deferred Revenue           4,900,000   4,900,000   5,700,000   3,100,000 3,100,000   4,900,000            
Research collaboration and license agreement period                     3 years                    
Cost of clinical development activities                               20,000,000          
Revenue from the performance of research services                       1,100,000 1,400,000                
Contract agreement period                                         5 years
Contract awarded to develop technology                                         17,000,000
Percentage of contract NIAID is funding                                         100.00%
Grants receivable                                   $ 400,000 $ 600,000 $ 600,000